Humphries has assisted various types of pharmaceutical companies in pioneering breakthroughs in the U.S. evaluation process, including but not limited to cell therapy, gene therapy, nucleic acid drugs, monoclonal antibodies, bispecific antibodies, antibody-drug conjugates (ADCs), microbiome drugs, oncolytic viruses, oncolytic bacteria, vaccines, chemical drugs, and herbal medicines. Additionally, Humphries has achieved records of project approval in less than two months from project initiation.
Humphries boasts a top-tier domestic advisory team comprising former FDA and NMPA reviewers, along with industry experts with diverse cultural, professional, and technical backgrounds. The company also has a proficient project management team.
Humphries has a language editing team consisting of four native English speakers from the pharmaceutical industry, assisting in the native language editing of submission documents.
With years of international registration experience, Humphries excels in FDA and NMPA submissions. The company has served over a hundred pharmaceutical companies from the United States, Europe, Japan, China, and other countries and regions.
Offices in both China and the United States ensure 24/7 communication with domestic and international clients and regulatory authorities.
Humphries has established a comprehensive confidentiality and security backup system from SOPs (Standard Operating Procedures) to software and hardware, ensuring the security of client information.
The overall success rate of projects approaches 100%.